Nano3D Biosciences announces our partnership with The Scripps Research Institute and Cold Springs Harbor Laboratory to advance high-throughput screening for cancer research, funded by the National Institute of Health and sponsored by Greiner Bio-One North America.
Check out the new paper from our collaborators at the University of Houston where they constructed a 3D culture using primary cardiomyocytes. They found that these constructs preserved both the phenotype and contractility of the cardiomyocytes in 3D. This model could be used as a simple means of testing cardiotoxicity in 3D cultures that replicate native tissue environment.
Read the paper here.
n3D and Biotek Instruments published an application note together in Biospektrum using their Cytation 5 to image migration of 3D cell cultures in the BiO Assay – Biospektrum (German)
Glauco Souza, President and CSO of Nano3D Biosciences, discusses Organovo and the future prospects and challenges in the bioprinting market – Motley Fool
n3D and SBH Sciences partner to offer services in lead compound optimization using magnetic 3D bioprinting – PR Newswire
n3D is pleased to announce an OEM agreement with Greiner Bio-One. Greiner Bio-One is a global leader in medical technology for clinical diagnostics, the pharmaceutical and diagnostic industries, and biotechnology. Greiner will sell and distribute n3D’s leading products in 3D cell culture and bioprinting under their label. We at n3D are excited to partner with Greiner Bio-One to help researchers develop organoids and assays with speed, reproducibility, and faithfulness to native tissue environments.
n3D highlights the ability to read viability using CellTiter-Glo® and RealTime-GloTM using magnetically 3D bioprinted spheroids – Promega PubHub
n3D Biosciences collaborates with LC Sciences to validate their high-throughput spheroid assay for toxicity screening in 3D environments – PRWeb
Read the paper
n3D is participating in this year’s Innovation Zone at the 2015 BIO International Convention with other NSF-funded early stage biomedical startups – NSF